{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:41:59Z","timestamp":1792212119648,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014417","name":"Fundamental Research Fund of Shandong University","doi-asserted-by":"publisher","award":["21310082164008"],"award-info":[{"award-number":["21310082164008"]}],"id":[{"id":"10.13039\/100014417","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.114037","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T11:43:43Z","timestamp":1638445423000},"page":"114037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy"],"prefix":"10.1016","volume":"228","author":[{"given":"Sha-Sha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-1733","authenticated-orcid":false,"given":"Jing-De","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-7821","authenticated-orcid":false,"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-8028","authenticated-orcid":false,"given":"Zhao-Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114037_bib1","first-page":"1195","article-title":"Elucidation of the mechanism enabling tumor selective prodrug monotherapy","volume":"58","author":"Bosslet","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.114037_bib2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00259-008-0744-y","article-title":"Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer","volume":"35","author":"Cao","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2021.114037_bib3","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-12-3779","article-title":"Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [C-11]docetaxel and positron emission tomography","volume":"19","author":"van der Veldt","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.114037_bib4","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s00259-010-1489-y","article-title":"Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients","volume":"37","author":"van der Veldt","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2021.114037_bib5","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.114037_bib6","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114037_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ph13090245","article-title":"Antibody-drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2021.114037_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.114037_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2021.114037_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2021.114037_bib11","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.114037_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jddst.2018.08.022","article-title":"Antibody-drug conjugates (ADCs): potent biopharmaceuticals to target solid and hematological cancers- an overview","volume":"48","author":"Goli","year":"2018","journal-title":"J.\u00a0Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2021.114037_bib13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2021.114037_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.114037_bib15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody-drug conjugates","volume":"78","author":"Garcia-Alonso","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.114037_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.114037_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ejmech.2018.12.035","article-title":"Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment","volume":"163","author":"Zhuang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114037_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd4519","article-title":"Principles in the design of ligand-targeted cancer therapeutics and imaging agents","volume":"14","author":"Srinivasarao","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.114037_bib19","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","article-title":"Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents","volume":"58","author":"Casi","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114037_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib7020016","article-title":"Small-format drug conjugates: a viable alternative to ADCs for solid tumours?","volume":"7","author":"Deonarain","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.ejmech.2021.114037_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2533\/chimia.2018.154","article-title":"Tumor targeting with small molecule-drug conjugates (SMDCs) - can they be better than ADCs?","volume":"72","author":"Altmann","year":"2018","journal-title":"Chimia"},{"key":"10.1016\/j.ejmech.2021.114037_bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1021\/jacs.7b13361","article-title":"Chemically defined antibody- and small molecule-drug conjugates for in\u00a0vivo tumor targeting applications: a comparative analysis","volume":"140","author":"Cazzamalli","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.114037_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-5-70","article-title":"Targeted drug delivery for cancer therapy: the other side of antibodies","volume":"5","author":"Firer","year":"2012","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2021.114037_bib24","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1002\/anie.201310709","article-title":"A\u00a0small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors","volume":"53","author":"Krall","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.114037_bib25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1535-7163.MCT-11-0566","article-title":"Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors","volume":"11","author":"Kurzrock","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2021.114037_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2019.11.002","article-title":"Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy","volume":"69","author":"Raj","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2021.114037_bib27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.tips.2020.08.001","article-title":"Cancer nanomedicines in an evolving oncology landscape","volume":"41","author":"Guo","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2021.114037_bib28","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.114037_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nantod.2019.02.005","article-title":"Clinical cancer nanomedicine","volume":"25","author":"Wolfram","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.ejmech.2021.114037_bib30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s11426-018-9397-5","article-title":"Precise nanomedicine for intelligent therapy of cancer","volume":"61","author":"Chen","year":"2018","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.ejmech.2021.114037_bib31","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1021\/ja505212y","article-title":"Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy","volume":"136","author":"Huang","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.114037_bib32","doi-asserted-by":"crossref","first-page":"18301","DOI":"10.1021\/acsami.0c00650","article-title":"ROS-responsive nanoparticles formed from RGD-epothilone B conjugate for targeted cancer therapy","volume":"12","author":"Xia","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejmech.2021.114037_bib33","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1021\/acs.bioconjchem.8b00657","article-title":"Small molecule nanodrug assembled of dual-anticancer drug conjugate for synergetic cancer metastasis therapy","volume":"29","author":"Li","year":"2018","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.114037_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apmt.2018.02.003","article-title":"Enzyme-sensitive biodegradable and multifunctional polymeric conjugate as theranostic nanomedicine","volume":"11","author":"Cai","year":"2018","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.ejmech.2021.114037_bib35","doi-asserted-by":"crossref","first-page":"1903243","DOI":"10.1002\/advs.201903243","article-title":"A\u00a0nanostrategy for efficient imaging-guided antitumor therapy through a stimuli-responsive branched polymeric prodrug","volume":"7","author":"Cai","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2021.114037_bib36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jconrel.2019.12.017","article-title":"Stimuli-responsive polymeric prodrug-based nanomedicine delivering nifuroxazide and doxorubicin against primary breast cancer and pulmonary metastasis","volume":"318","author":"Luo","year":"2020","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2021.114037_bib37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.apsb.2020.07.023","article-title":"Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment","volume":"11","author":"Cai","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2021.114037_bib38","first-page":"6387","article-title":"A\u00a0new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.114037_bib39","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.114037_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/micc.12228","article-title":"A\u00a0retrospective 30 Years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy--problems, solutions, and prospects","volume":"23","author":"Maeda","year":"2016","journal-title":"Microcirculation"},{"key":"10.1016\/j.ejmech.2021.114037_bib41","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2021.114037_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications","volume":"203","author":"D'Souza","year":"2015","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2021.114037_bib43","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1039\/C4NR06714B","article-title":"Galactose-functionalized multi-responsive nanogels for hepatoma-targeted drug delivery","volume":"7","author":"Lou","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejmech.2021.114037_bib44","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1039\/C6CC05707A","article-title":"Galactose-decorated light-responsive hydrogelator precursors for selectively killing cancer cells","volume":"52","author":"Ji","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2021.114037_bib45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bmcl.2006.11.008","article-title":"Synthesis of 2 '-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells","volume":"17","author":"Liu","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114037_bib46","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1016\/j.biomaterials.2012.04.047","article-title":"The inhibition of tumor growth and metastasis by self-assembled nanofibers of taxol","volume":"33","author":"Wang","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2021.114037_bib47","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1021\/bc400210x","article-title":"Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery","volume":"24","author":"Mura","year":"2013","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.114037_bib48","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/ja909475m","article-title":"Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery","volume":"132","author":"Shen","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.114037_bib49","doi-asserted-by":"crossref","first-page":"1703135","DOI":"10.1002\/adma.201703135","article-title":"Self-assembly of an amphiphilic janus camptothecin-floxuridine conjugate into liposome-like nanocapsules for more efficacious combination chemotherapy in cancer","volume":"29","author":"Liang","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejmech.2021.114037_bib50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: a review of adverse toxicities and novel delivery strategies","volume":"6","author":"Marupudi","year":"2007","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2021.114037_bib51","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: what has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int. J. Pharm."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:33:38Z","timestamp":1759329218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421008862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["S0223523421008862"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114037","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114037"}}